An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

July 31, 2020

Conditions

Advanced Solid Tumors

Interventions

DRUG

PT-112 Injection

PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai